Aineistot 1-2 / 2
PARP Inhibitors in Prostate Cancer – The Preclinical Rationale and Current Clinical Development
Prostate cancer is the second most commonly diagnosed cancer type in men in the Western world. The majority of prostate cancer patients have a good prognosis, while some prostate cancers advance locally or metastasize. ...
SUMOylation regulates nuclear accumulation and signaling activity of the ErbB4 receptor tyrosine kinase
Erb-B2 receptor tyrosine kinase 4 (ErbB4) is a kinase that can signal via a proteolytically released intracellular domain (ICD) in addition to classical receptor tyrosine kinase–activated signaling cascades. Previously, ...